. Taking part in this study will last between 22-28 weeks. The purpose of this study is to assess a study drug called etrasimod in the treatment of Crohn’s disease (CD).
Criteria:· are 18‒80 years of age
· have been diagnosed with moderately to severely active Crohn's Disease (CD) for at least 3 months
· did not respond to CD therapy, responded to CD therapy at first but are no longer responding, or could not tolerate available CD therapies.